SELECT LANGUAGE BELOW

Should You Buy, Sell, or Hold Bristol Myers Squibb in 2026?

Should You Buy, Sell, or Hold Bristol Myers Squibb in 2026?

Bristol-Myers Squibb has been struggling financially in recent times. The pharmaceutical leader is facing issues like multiple patent expirations. Still, it remains appealing due to new product launches, advancements in its pipeline, and dividend offerings. The last five years have not been easy for Bristol-Myers Squibb (NYSE:BMY). The company has lost patent protection on crucial […]